d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
   PubMed Web of Science ®Google Scholar
• Hahn S, Bering van Halteren W, Kimmig R, et al. Diagnostic procedures in polycystic ovary syndrome. J Lab Med 2003;27:53–9
   Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006;21:1400–7
   PubMed Web of Science ®Google Scholar
• Ciotta L, Calogero AE, Farina M, et al. Clinical, endocrine and metabolic effects of acarbose: an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Hum Reprod 2001;16:2066–72
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626–32
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80
   PubMed Web of Science ®Google Scholar
• Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310–15
   PubMed Web of Science ®Google Scholar
• Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 2010;4:359–64
   PubMedGoogle Scholar
• Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407–13
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a d-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127–36
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of alpha-lipoic acid. Endocr Pract 2002;8:29–35
   PubMedGoogle Scholar
• Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 2010;4:359–64
   PubMedGoogle Scholar
• Capasso I, Esposito E, Maurea N, et al. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 2013;14:273–9
   PubMedGoogle Scholar
• The Rotterdam ESHRE/ARSM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus ion diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMedGoogle Scholar
• Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999;71:319–22
   PubMed Web of Science ®Google Scholar
• Dinicola S, Chiu TT, Unfer V, et al. The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 2014;54:1079–92
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30:438–43
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2014;18:1896–903
   PubMed Web of Science ®Google Scholar
• Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res 2013;40:51–63
   PubMed Web of Science ®Google Scholar
• Piomboni P, Focarelli R, Capaldo A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet 2014;31:1269–76
   PubMed Web of Science ®Google Scholar
• Desai V, Prasad NR, Manohar SM, et al. Oxidative stress in non-obese women with polycystic ovarian syndrome. J Clin Diagn Res 2014;8:CC01–3
   PubMedGoogle Scholar
• Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066–71
   PubMed Web of Science ®Google Scholar
• Uzel N, Sivas A, Uysal M, Oz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm Metab Res 1987;19:89–90
   PubMed Web of Science ®Google Scholar
• Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod 1997;12:53–62
   PubMedGoogle Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–9
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Despini G, Santagni S, et al. Effects of a Combination of Alpha Lipoic Acid and Myo-Inositol on Insulin Dynamics in Overweight/Obese Patients with PCOS. Endocrinol Metab Syndr 2014;3:140
   Google Scholar
• Cappelli V, Di Sabatino A, Musacchio MC, De Leo V. Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS. Minerva Ginecol 2013;65:425–33
   PubMedGoogle Scholar
• Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000;2:401–13
   PubMedGoogle Scholar
• Asemi Z, Samimi M, Tabassi Z, et al. Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized clinical trial. Nutrition 2014;30:1287–93
   PubMed Web of Science ®Google Scholar
• La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2014;30:1–5
   Google Scholar